|
Metastasis from malignant tumor of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that there was a significant correlation between MMP9 and AR protein expression in primary and metastatic PCa tissues, and a trend that high level of MMP9 expression was associated with poor prognosis.
|
31381135 |
2020 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer.
|
31604846 |
2020 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antiandrogens have a peculiar place in the treatment of metastatic prostate cancer by blocking the androgen receptor (AR).
|
30831197 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Then the development, the performance evaluation and contextualization in a clinical setting of this standardized operating procedure (SOP) have been reported to evaluate the prognostic biomarker AR-V7 in metastatic prostate cancer.
|
30141201 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TTCCs were upregulated in PCas harboring androgen receptor (AR) mutations; CNV rate was positively associated with PCa progression.
|
31334879 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer.
|
31117038 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
As second-generation androgen receptor antagonists have been increasingly used for treatment of castration-resistant stage metastatic prostate cancer, new onset of symptomatic epidural lipomatosis should be considered as a possible differential diagnosis, especially because the urinary symptoms of cauda equina compression may be improperly attributed to the primary prostate neoplasm.
|
30763756 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Adaptive resistance of metastatic prostate cancer to enzalutamide treatment can be due to the activation of both androgen receptor (AR)-dependent pathways (expression of constitutively active AR splice variants, AR point mutations, gene amplification and overexpression) and mechanisms independent of AR signaling pathway (altered steroidogenesis, upregulation of the glucocorticoid receptor, epithelial-mesenchymal transition, neuroendocrine transformation, autophagy and activation of the immune system).
|
30425524 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy.
|
29644451 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed that AR, MMP-9 and EGFR are interconnect factors, which may cooperatively promote PCa progression.
|
30134822 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study also highlights that approaches to target advanced PC require intelligent combination of agents to target single/multiple signalling pathways in combination with androgen receptor (AR) blockade.
|
29314004 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies.
|
29530945 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting androgen receptor (AR) signaling with androgen deprivation therapy (ADT) represents the mainstay of therapy for advanced and metastatic prostate cancer.
|
30396917 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer.
|
30135575 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The standard treatment for metastatic prostate cancer, androgen deprivation therapy (ADT), is designed to suppress androgen receptor (AR) activity.
|
30242112 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is the mainstay of (metastatic) prostate cancer therapy.
|
29276148 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from the present study suggest that 3α-diol may act as an alternative intra-prostatic neurosteroid that activates AR-independent PCa progression.
|
29155210 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selectivity in coregulator-dependent AR action is reflected in differential AR binding site composition and involvement with CaP biology and progression.
|
28826481 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer progression is controlled by the androgen receptor and new blood vessel formation, or angiogenesis, which promotes metastatic prostate cancer growth.
|
28394264 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While modern therapies for metastatic prostate cancer (PCa) have improved survival they are associated with an increasingly prevalent entity, aggressive variant PCa (AVPCa), lacking androgen receptor (AR) expression, enriched for cancer stem cells (CSCs), and evidencing epithelial-mesenchymal plasticity with a varying extent of neuroendocrine transdifferentiation.
|
28103576 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
|
28925066 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel AR signaling pathway that induces microRNA-1 (miR-1) to suppress metastatic prostate cancer was recently demonstrated (AR-miR-1 signaling axis), and its regulation of Wnt signaling was explored in the current study.
|
28220803 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting the androgen receptor (AR) pathway is an important clinical strategy in metastatic prostate cancer.
|
28219796 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for treating metastatic prostate cancer (mPC).
|
29017058 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although potent androgen receptor pathway inhibitors (ARPI) improve overall survival of metastatic prostate cancer patients, treatment-induced neuroendocrine prostate cancer (t-NEPC) as a consequence of the selection pressures of ARPI is becoming a more common clinical issue.
|
28427194 |
2017 |